Adicet Bio completes last patient visit for planned prula-cel analysis
Adicet Bio (ACET) said it has completed the last patient visit for the planned analysis of its prula-cel (formerly ADI-001) study in systemic lupus erythematosus with or without lupus nephritis, and provided a corporate update.
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned P…